To investigate if pharmacological inhibition of PI3K p110α successfully attenuates basal Akt/mTOR signaling pathway activation, we performed Western blot analysis of GBM cells treated with three different PI3K p110α-specific inhibitors (YM024, A66, or PIK75). This evidence concerns the gene AKT1 and glioblastoma.